High Risk of false positive
This profile might be a false positive : due to probable homonyms, we think this profile may contain incorrect informations.
Please read FAQ for more information.

Number of publications published per year by Sigal, Samuel. (Source : PubMed)

Distribution of publications types for Sigal, Samuel. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)



Rifaximin treatment in hepatic encephalopathy.
N. Engl. J. Med.
2010;362;12




A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
Gastroenterology
2008;134;5



Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
N. Engl. J. Med.
2007;357;22
Future therapies for hepatitis C: where do we go from here?
Nature clinical practice. Gastroenterology & hepatology
2007;4;2
[ See timeline ] [ See all publications ]
means that Sigal, Samuel has 15 papers cited a least 15 times - methodology
University of California, San Francisco, San Francisco, California, USA.
Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.